118 related articles for article (PubMed ID: 20669296)
1. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease.
Stocchi F; Zappia M; Dall'Armi V; Kulisevsky J; Lamberti P; Obeso JA;
Mov Disord; 2010 Sep; 25(12):1881-7. PubMed ID: 20669296
[TBL] [Abstract][Full Text] [Related]
2. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
Ondo WG; Shinawi L; Moore S
Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
[TBL] [Abstract][Full Text] [Related]
3. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease.
Stocchi F; Fabbri L; Vecsei L; Krygowska-Wajs A; Monici Preti PA; Ruggieri SA
Clin Neuropharmacol; 2007; 30(1):18-24. PubMed ID: 17272966
[TBL] [Abstract][Full Text] [Related]
6. Sinemet CR in Parkinson's disease.
Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
[TBL] [Abstract][Full Text] [Related]
7. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
9. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
[TBL] [Abstract][Full Text] [Related]
10. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
Mark MH; Sage JI
Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
[TBL] [Abstract][Full Text] [Related]
11. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Metman LV; Hoff J; Mouradian MM; Chase TN
Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
[TBL] [Abstract][Full Text] [Related]
12. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
13. Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study.
Zangaglia R; Stocchi F; Sciarretta M; Antonini A; Mancini F; Guidi M; Martignoni E; Pacchetti C
Clin Neuropharmacol; 2010; 33(2):61-6. PubMed ID: 19935405
[TBL] [Abstract][Full Text] [Related]
14. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
Rondot P; Ziegler M; Aymard N; Teinturier A
Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
Jankovic J; Schwartz K; Vander Linden C
Mov Disord; 1989; 4(4):303-9. PubMed ID: 2682215
[TBL] [Abstract][Full Text] [Related]
16. Sinemet in Parkinson's disease: efficacy with and without food.
Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB
Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604
[No Abstract] [Full Text] [Related]
17. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH
Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
[TBL] [Abstract][Full Text] [Related]
18. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
[TBL] [Abstract][Full Text] [Related]
19. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC
Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Pahwa R; Koller WC
Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
[No Abstract] [Full Text] [Related]
[Next] [New Search]